VIVA BIOTECH (01873) announced that its wholly-owned subsidiary, Zhejiang Langhua Pharmaceutical Co., Ltd., recently received a response from the Taizhou Municipal Bureau of Ecology and Environment regarding the environmental impact report submitted for the proposed production of certain peptide and other small-molecule drug advanced intermediates. This response approves Langhua Pharmaceutical's plan, as detailed in the environmental impact report, to renovate three existing plants within the Zhejiang Chemical Raw Material Drug Base in Linhai Park to manufacture these advanced intermediates for peptides and other small-molecule drugs. Langhua Pharmaceutical intends to implement the production plan outlined in the environmental impact report, adhering to the requirements specified in the response and managing the project in compliance with relevant laws and regulations, aiming to commence production as soon as feasibly possible. The production plan is expected to drive the Group's business growth and enhance its production capabilities and capacity, thereby benefiting the Group. The company hereby states that it has not made any forecasts or predictions regarding the impact of this production plan on the Group's profits.